PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 10 | 1 | 61-70
Article title

Endometrioza i proces nowotworowy

Content
Title variants
EN
Endometriosis and the neoplastic process
Languages of publication
EN PL
Abstracts
EN
Endometriosis is a benign proliferative process, where tissues of the uterine mucosa are present ectopically, generally manifesting by infertility and pain. Awareness of similarity between endometriosis and neoplastic process, as well as of oncological risk associated therewith is low. Since 1925, when Sampson was the first to highlight the fact that endometriosis may transform into a malignant lesion, several papers appeared in the medical literature extensively documenting the correlation between endometriosis and tumors, in particular with ovarian cancer. The aim of this paper was to examine correlations linking endometriosis with the neoplastic process by reviewing medical literature published in English in the aspect of epidemiological evidence of endometriosis – cancer correlation, comparison of clinical-pathological features of both entities and comparison of molecular and genetic features of endometriosis with the “cancer phenotype” as defined by Hanahan and Weinberg in their paper The hallmarks of cancer. A large body of evidence has been collected documenting similarity of endometriosis to the neoplastic process, its association with malignant transformation and increased risk of cancer and other malignant tumors. It is not clear, whether endometriotic lesions may undergo malignant transformation directly, indirectly with an intermediate phase, the so-called atypical endometriosis, or endometriosis and cancer possess common initial antecedent mechanisms and/or predisposing factors (e.g. genetic susceptibility, sensitivity to exposure to environmental toxins) with subsequent divergence on the molecular level. Incidence of endometriosis undoubtedly creates an oncological risk, necessitating elucidation by further genetic and molecular studies.
PL
Endometrioza to łagodny proces rozrostowy, w którym tkanki błony śluzowej macicy występują ekotopowo. Schorzenie kojarzone jest powszechnie z niepłodnością oraz z bólem. Mała jest świadomość podobieństw endometriozy do procesu nowotworowego oraz zagrożeń onkologicznych związanych z jej występowaniem. Od 1925 roku, kiedy Sampson jako pierwszy zwrócił uwagę, że endometrioza może przekształcić się w zmianę złośliwą, w literaturze medycznej pojawiły się liczne publikacje obszernie dokumentujące związek gruczolistości z nowotworami, a w szczególności z rakiem jajnika. Celem pracy było zbadanie powiązań endometriozy z procesem nowotworowym poprzez przeszukanie anglojęzycznego piśmiennictwa medycznego pod kątem dowodów epidemiologicznych na związek endometriozy z rakiem, porównania cech kliniczno-patologicznych endometriozy i raka oraz porównanie cech molekularnych i genetycznych endometriozy z cechami „fenotypu raka” zdefiniowanymi przez Hanahana i Weinberga w publikacji zatytułowanej The hallmarks of cancer. Zebrano liczne dowody dużego podobieństwa endometriozy do procesu nowotworowego, związku z transformacją złośliwą oraz ze zwiększonym ryzykiem raka i innych nowotworów złośliwych. Nie jest jasne, czy zmiany endometriotyczne mogą bezpośrednio ulegać przemianie złośliwej, z etapem pośrednim, tzw. atypowej endometriozy, czy też endometrioza oraz rak posiadają wyłącznie wspólne początkowe, antecendentne mechanizmy i/lub czynniki predysponujące (np. genetyczną podatność, wrażliwość na ekspozycję toksynami środowiskowymi) z oczywistą dywergencją w przebiegu molekularnym. Występowanie endometriozy niewątpliwie stwarza zagrożenie onkologiczne, którego źródło powinno być wyjaśnione poprzez dalsze badania genetyczne i molekularne.
Discipline
Publisher

Year
Volume
10
Issue
1
Pages
61-70
Physical description
Contributors
  • Katedra i Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Ginekologicznej, Gdański Uniwersytet Medyczny, ul. Kliniczna 1 A, 80-401 Gdańsk, tel.: 58 349 34 36. Kierownik Katedry i Kliniki: dr hab. n. med. Dariusz Wydra, jacek.sznurkowski@gumed.edu.pl
References
  • 1. Rokitansky K.: Über Uterusdrüsen-Neubildung in Uterus- und Ovarial-Sarcomen. Ztsch. K. K. Gessellsch. der Aerzte zu Wien 1860; 16: 577-581.
  • 2. Nisolle M., Donnez J.: Peritoneal endometriosis, ovarian endo- metriosis, and adenomyaotic nodules of the rectovaginal septum are three different entities. Fertil. Steril. 1997; 68: 585-595.
  • 3. Busacca M., Vignali M.: Ovarian endometriosis: from pathoge- nesis to surgical treatment. Curr. Opin. Obstet. Gynecol. 2003; 15: 321-326.
  • 4. Varma R., Rollason T., Gupta J.K. i wsp.: Endometriosis and the neoplastic process. Reproduction 2004; 127: 293-304.
  • 5. Practice Committee of the American Society for Reproductive Medicine: Endometriosis and infertility. Fertil. Steril. 2004; 81: 1441-1446.
  • 6. Sampson J.A.: Endometrial carcinoma of the ovary arising in endometrial tissue in that organ. Arch. Surg. 1925; 10: 1-72.
  • 7. Erzen M., Kovacic J.: Relationship between endometriosis and ovarian cancer. Eur. J. Gynaecol. Oncol. 1998; 19: 553-555.
  • 8. Modesitt S.C., Tortolero-Luna G., Robinson J.B. i wsp.: Ova- rian and extraovarian endometriosis-associated cancer. Obstet. Gynecol. 2002; 100: 788-795.
  • 9. Stern R.C., Dash R., Bentley R.C. i wsp.: Malignancy in endo- metriosis: frequency and comparison of ovarian and extraova- rian types. Int. J. Gynecol. Pathol. 2001; 20: 133-139.
  • 10. Zaino R., Whitney C., Brady M.F. i wsp.: Simultaneously detected endometrial and ovarian carcinomas – a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol. Oncol. 2001; 83: 355-362.
  • 11. Seidman J.D.: Prognostic importance of hyperplasia and atypia in endometriosis. Int. J. Gynecol. Pathol. 1996; 15: 1-9.
  • 12. Nishida M., Watanabe K., Sato N., Ichikawa Y.: Malignant transformation of ovarian endometriosis. Gynecol. Obstet. Invest. 2000; 50 supl. 1: 18-25.
  • 13. Al-Fazan H., Tulandi T.: Left lateral predisposition of endome- triosis and endometrioma. Obstet. Gynecol. 2003; 101: 164-166.
  • 14. Sznurkowski J.J., Emerich J.: Endometriomas are more frequ- ent on the left side. Acta Obstet. Gynecol. Scand. 2008; 87: 104-106.
  • 15. Vercellini P., Scarfone G., Bolis G. i wsp.: Site of origin of epi- thelial ovarian cancer: the endometriosis connection. BJOG 2000; 107: 1155-1157.
  • 16. National Statistics 2003 Cancer trends in England and Wales 1950-1999 (UK Government).
  • 17. Fukunaga M., Nomura K., Ishikawa E. i wsp.: Ovarian atypi- cal endometriosis: its close association with malignant epithe- lial tumours. Histopathology 1997; 30: 249-255.
  • 18. Ogawa S., Kaku T., Amada S. i wsp.: Ovarian endometrio- sis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol. Oncol. 2000; 77: 298-304.
  • 19. Oral E., Ilvan S., Tustas E. i wsp.: Prevalence of endometriosis in malignant epithelial ovary tumours. Eur. J. Obstet. Gynecol. Reprod. Biol. 2003; 109: 97-101.
  • 20. Lapp T.: ACOG issues recommendations for the management of endometriosis. American College of Obstetricians and Gyne- cologists. Am. Fam. Physician 2000; 62: 1431, 1434.
  • 21. Brinton L.A., Gridley G., Persson I. i wsp.: Cancer risk after a hospital discharge diagnosis of endometriosis. Am. J. Obstet. Gynecol. 1997; 176: 572-579.
  • 22. Yoshikawa H., Jimbo H., Okada S. i wsp.: Prevalence of endo- metriosis in ovarian cancer. Gynecol. Obstet. Invest. 2000; 50 supl. 1: 11-17.
  • 23. Pecorelli S., Odicino F., Maisonneuve P. i wsp.: Carcinoma of the ovary. Annual report on the results of treatment in gyna- ecological cancer. J. Epidemiol. Biostat. 1998; 3: 75-102.
  • 24. Erzen M., Rakar S., Klancar B. i wsp.: Endometriosis-associa- ted ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol. Oncol. 2001; 83: 100-108.
  • 25. Melin A., Sparén P., Persson I., Bergqvist A.: Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum. Reprod. 2006; 21: 1237-1242.
  • 26. Seidman J.D.: Prognostic importance of hyperplasia and aty- pia in endometriosis. Int. J. Gynecol. Pathol. 1996; 15: 1-9.
  • 27. Bayramoğlu H., Düzcan E.: Atypical epithelial changes and mutant p53 gene expression in ovarian endometriosis. Pathol. Oncol. Res. 2001; 7: 33-38.
  • 28. Kronqvist P., Kuopio T., Jalava P., Collan Y.: Morphometrical malignancy grading is a valuable prognostic factor in invasive ductal breast cancer. Br. J. Cancer 2002; 87: 1275-1280.
  • 29. Regidor P.A., Wagner I., Ruwe M. i wsp.: Morphometric analy- ses of endometriotic tissues to determine their grade of activity. Gynecol. Endocrinol. 2002; 16: 235-243.
  • 30. Ballouk F., Ross J.S., Wolf B.C.: Ovarian endometriotic cysts. An analysis of cytologic atypia and DNA ploidy patterns. Am. J. Clin. Pathol. 1994; 102: 415-419.
  • 31. Hanahan D., Weinberg R.A.: The hallmarks of cancer. Cell 2000; 100: 57-70.
  • 32. Bulun S.E., Zeitoun K.M., Takayama K., Sasano H.: Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance. J. Mol. Endocrinol. 2000; 25: 35-42.
  • 33. Matsuzaki S., Murakami T., Uehara S. i wsp.: Expression of estrogen receptor alpha and beta in perito-neal and ovarian endometriosis. Fertil. Steril. 2001; 75: 1198-1205.
  • 34. Kitawaki J., Obayashi H., Ishihara H. i wsp.: Oestrogen recepto- r-alpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. Hum. Reprod. 2001; 16: 51-55.
  • 35. Wieser F., Schneeberger C., Tong D. i wsp.: PROGINS recep- tor gene polymorphism is associated with endometriosis. Fertil. Steril. 2002; 77: 309-312.
  • 36. Baranova H., Canis M., Ivaschenko T. i wsp.: Possible involve- ment of arylamine N-acetyltransferase 2, glutathione S-transfe- rases M1 and T1 genes in the development of endometriosis. Mol. Hum. Reprod. 1999; 5: 636-641.
  • 37. Hadfield R.M., Manek S., Weeks D.E. i wsp.: Linkage and asso- ciation studies of the relationship between endometriosis and genes encoding the detoxification enzymes gSTM1 , gSTT1 and Cyp1a1 . Mol. Hum. Reprod. 2001; 7: 1073-1078.
  • 38. Nakago S., Hadfield R.M., Zondervan K.T. i wsp.: Association between endometriosis and N-acetyl transferase 2 polymorphisms in a UK population. Mol. Hum. Reprod. 2001; 7: 1079-1083.
  • 39. Arvanitis D.A., Koumantakis G.E., Goumenou A.G. i wsp.: Cyp1a1 , Cyp19 , and gSTM1 polymorphisms increase the risk of endometriosis. Fertil. Steril. 2003; 79 supl. 1: 702-709.
  • 40. Baxter S.W., Thomas E.J., Campbell I.G.: gSTM1 null poly- morphism and susceptibility to endometriosis and ovarian cancer. Carcinogenesis 2001; 22: 63-65.
  • 41. Birnbaum L.S., Cummings A.M.: Dioxins and endometriosis: a plausible hypothesis. Environ. Health Perspect. 2002; 110: 15-21.
  • 42. Eskenazi B., Mocarelli P., Warner M. i wsp.: Serum dioxin con- centrations and endometriosis: a cohort study in Seveso, Italy. Environ. Health Perspect. 2002; 110: 629-634.
  • 43. Bulun S.E., Zeitoun K.M., Kilic G.: Expression of dioxin-rela- ted transactivating factors and target genes in human eutopic endometrial and endometriotic tissues. Am. J. Obstet. Gyne- col. 2000; 182: 767-775.
  • 44. Ohtake F., Takeyama K., Matsumoto T. i wsp.: Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 2003; 423: 545-550.
  • 45. Lebovic D.I., Mueller M.D., Taylor R.N.: Immunobiology of endometriosis. Fertil. Steril. 2001; 75: 1-10.
  • 46. Druckmann R., Rohr U.D.: IGF-1 in gynaecology and obste- trics: update 2002. Maturitas 2002; 41 supl. 1: S65-S83.
  • 47. Matsuzaki S., Canis M., Murakami T. i wsp.: Expression of the cyclin-dependent kinase inhibitor p27Kip1 in eutopic endome- trium and peritoneal endometriosis. Fertil. Steril. 2001; 75: 956-960.
  • 48. Fauvet R., Poncelet C., Hugol D. i wsp.: Expression of apopto- sis-related proteins in endometriomas and benign and mali- gnant ovarian tumours. Virchows Arch. 2003; 443: 38-43.
  • 49. Attia G.R., Zeitoun K., Edwards D. i wsp.: Progesterone recep- tor isoform A but not B is expressed in endometriosis. J. Clin. Endocrinol. Metab. 2000; 85: 2897-2902.
  • 50. Meresman G.F., Vighi S., Buquet R.A. i wsp.: Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil. Steril. 2000; 74: 760-766.
  • 51. Ria R., Loverro G., Vacca A. i wsp.: Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 agree with progression of ovarian endometriomas. Eur. J. Clin. Invest. 2002; 32: 199-206.
  • 52. Ueda M., Yamashita Y., Takehara M. i wsp.: Survivin gene expression in endometriosis. J. Clin. Endocrinol. Metab. 2002; 87: 3452-3459.
  • 53. Garcia-Velasco J.A., Mulayim N., Kayisli U.A., Arici A.: Eleva- ted soluble Fas ligand levels may suggest a role for apoptosis in women with endometriosis. Fertil. Steril. 2002; 78: 855-859.
  • 54. Vidal J.D., Register T.C., Gupta M. i wsp.: Estrogen replace- ment therapy induces telomerase RNA expression in the maca- que endometrium. Fertil. Steril. 2002; 77: 601-608.
  • 55. Wang Z., Kyo S., Maida Y. i wsp.: Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression dif- ferently in breast and endometrial cancer cells. Oncogene 2002; 21: 3517-3524.
  • 56. Folkman J.: Role of angiogenesis in tumor growth and meta- stasis. Semin. Oncol. 2002; 29 supl. 16: 15-18.
  • 57. Gazvani R., Templeton A.: Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction 2002; 23: 217-226.
  • 58. Kitawaki J., Obayashi H., Ohta M. i wsp.: Genetic contribution of the interleukin-10 promoter polymorphism in endometriosis susceptibility. Am. J. Reprod. Immunol. 2002; 47: 12-18.
  • 59. Viganò P., Infantino M., Lattuada D. i wsp.: Intercellular adhe- sion molecule-1 (ICAM-1) gene polymorphisms in endome- triosis. Mol. Hum. Reprod. 2003; 9: 47-52.
  • 60. Wieser F., Fabjani G., Tempfer C. i wsp.: Analysis of an interleuki- n-6 gene promoter polymorphism in women with endometriosis by pyrosequencing. J. Soc. Gynecol. Investig. 2003; 10: 32-36.
  • 61. Landi S., Moreno V., Gioia-Patricola L. i wsp.; Bellvitge Colo- rectal Cancer Study Group: Association of common polymor- phisms in inflammatory genes interleukin (il )6, il8 , tumor necrosis factor α, NFKB1, and peroxisome proliferator-activa- ted receptor γ with colorectal cancer. Cancer Res. 2003; 63: 3560-3566.
  • 62. Hull M.L., Charnock-Jones D.S., Chan C.L. i wsp.: Antiangio- genic agents are effective inhibitors of endometriosis. J. Clin. Endocrinol. Metab. 2003; 88: 2889-2899.
  • 63. Dabrosin C., Gyorffy S., Margetts P. i wsp.: Therapeutic effect of angiostatin gene transfer in a murine model of endometrio- sis. Am. J. Pathol. 2002; 161: 909-918.
  • 64. Kokorine I., Nisolle M., Donnez J. i wsp.: Expression of inter- stitial collagenase (matrix metalloproteinase-1) is related to the activity of human endometriotic lesions. Fertil. Steril. 1997; 68: 246-251.
  • 65. Nezhat F.R., Kalir T.: Comparative immunohistochemical stu- dies of endometriosis lesions and endometriotic cysts. Fertil. Steril. 2002; 78: 820-824.
  • 66. Mizumoto H., Saito T., Ashihara K. i wsp.: Expression of matrix metalloproteinases in ovarian endometriomas: immu- nohistochemical study and enzyme immunoassay. Life Sci. 2002; 71: 259-273.
  • 67. Morin P.J.: β-catenin signaling and cancer. Bioessays 1999; 21: 1021-1030.
  • 68. Scotti S., Regidor P.A., Schindler A.E. i wsp.: Reduced prolife- ration and cell adhesion in endometriosis. Mol. Hum. Reprod. 2000; 6: 610-617.
  • 69. Witz C.A., Takahashi A., Montoya-Rodriguez I.A. i wsp.: Expression of the α2β1 and α3β1 integrins at the surface of mesothelial cells: a potential attachment site of endometrial cells. Fertil. Steril. 2000; 74: 579-584.
  • 70. Chen G.T., Tai C.T., Yeh L.S. i wsp.: Identification of the cadherin subtypes present in the human peritoneum and endo- metriotic lesions: potential role for P-cadherin in the develop- ment of endometriosis. Mol. Reprod. Dev. 2002; 62: 289-294.
  • 71. Ueda M., Yamashita Y., Takehara M. i wsp.: Gene expression of adhesion molecules and matrix metalloproteinases in endo- metriosis. Gynecol. Endocrinol. 2002; 16: 391-402.
  • 72. Foidart J.M., Beliard A., Donnez J.: Endometriosis and inva- sion. W: Brosens I., Donnez J. (red.): The Current Status of Endometriosis Research and Management. Parthenon Pub- lishing, Carnforth 1993: 35-39.
  • 73. Beliard A., Donnez J., Nisolle M., Foidart J.M.: Localization of laminin, fibronectin, E-cadherin, and integrins in endometri- um and endometriosis. Fertil. Steril. 1997; 67: 266-272.
  • 74. Lessey B.A., Damjanovitch L., Coutifaris C. i wsp.: Integrin adhesion molecules in the human endometrium: correlation with the normal and abnormal menstrual cycle. J. Clin. Invest. 1992; 90: 188-195.
  • 75. Tabibzadeh S., Sun X.Z.: Cytokine expresion in human endo- metrium through the menstrual cycle. Hum. Reprod. 1992; 7: 1214-1221.
  • 76. Bridges J.E., Prentice A., Roche W. i wsp.: Expression of integ- rin adhesion molecules in endometrium and endometriosis. Br. J. Obstet. Gyneacol. 1994; 101: 696-700.
  • 77. van der Linden P.J., de Goeij A.F., Dunselman G.A. i wsp.: Expression of cadherins and integrins in human endometri- um throughout the menstrual cycle. Fertil. Steril. 1995; 63: 1210-1216.
  • 78. Starzinski-Powitz A., Handrow-Metzmacher H., Kotzian S.: The putative role of cell adhesion molecules in endometriosis: can we learn from tumour metastasis? Mol. Med. Today 1999; 5: 304-309.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-7ae840aa-7c3e-4b97-930a-d4b4cd18d783
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.